Copyright
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Nov 15, 2019; 11(11): 1065-1080
Published online Nov 15, 2019. doi: 10.4251/wjgo.v11.i11.1065
Published online Nov 15, 2019. doi: 10.4251/wjgo.v11.i11.1065
Clinical significance of MLH1/MSH2 for stage II/III sporadic colorectal cancer
Shui-Ming Wang, Bin Jiang, National Center of Colorectal Disease, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing 210022, Jiangsu Province, China
Youping Deng, Yu Wang, Bioinformatics Core, Department of Complementary and Integrative Medicine, University of Hawaii John A. Burns School of Medicine, Honolulu, HI 96813, United States
Shu-Liang Huang, Department of Pathology, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing 210022, Jiangsu Province, China
Ming-Zhi Fang, Yu Wang, Department of Oncology, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing 210022, Jiangsu Province, China
Author contributions: Wang SM and Wang Y performed the study and drafted the manuscript; Jiang B and Deng YP designed the study; Huang SL performed the experiments; Fang MZ enrolled the patients and acquired the follow-up data; Jiang B coordinated the study and analyzed the data; all the authors contributed to, read, and approved the final manuscript.
Supported by Medical Science and Technology Development Foundation , Nanjing Department of Health, No. YKK14140 (to Shui-Ming Wang) and No. ZKX15040 (to Bin Jiang) ; Project of Administration of Traditional Chinese Medicine of Jiangsu Province of China , No. LZ11101 (to Zhi-Ming Fang) .
Institutional review board statement: The study was reviewed and approved by the Institutional Review Board of Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine.
Informed consent statement: All participants provided informed consent prior to study enrollment.
Conflict-of-interest statement: All authors have no conflict of interest to disclose.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement checklist of items, and the manuscript was prepared and revised according to the STROBE Statement checklist of items.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Yu Wang, MD, PhD, Chief Doctor, Department of Oncology, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing 210022, Jiangsu Province, China christinewangyu@outlook.com
Telephone: +86-17327005861 Fax: +86-25-627364
Received: April 29, 2019
Peer-review started: May 9, 2019
First decision: July 31, 2019
Revised: August 10, 2019
Accepted: September 10, 2019
Article in press: September 10, 2019
Published online: November 15, 2019
Processing time: 201 Days and 0 Hours
Peer-review started: May 9, 2019
First decision: July 31, 2019
Revised: August 10, 2019
Accepted: September 10, 2019
Article in press: September 10, 2019
Published online: November 15, 2019
Processing time: 201 Days and 0 Hours
Core Tip
Core tip: Mutation or methylation of mismatch repair gene leads to microsatellite instability (MSI), which is one of the most important mechanisms for the development of colorectal cancer (CRC). The purpose of this study was to collect data on MLH1/MSH2 phenotype and MSI status in stage II-III CRC patients and to assess their predictive and prognostic value. This is the first large study in China to evaluate the role of MLH1/MSH2 in CRC and its relationship with adjuvant chemotherapy.